Liftstream is an executive search recruitment company in the life sciences sector
Wellstat Therapeutics given FDA nod for XURIDEN in Rare Disease
Wellstat Therapeutics Corporation has announced in September that the US Food and Drug Administration granted marketing approval for XURIDEN™ (uridine triacetate), a pyrimidine analog for uridine replacement indicated for the treatment of hereditary orotic aciduria (HOA). With the approval of … Continue reading
Psoriasis drug dropped by Amgen goes to Valeant
Valeant Pharmaceuticals is a very aggressive acquirer of companies and assets. The Canadian company has most recently purchased the rights to an asset from AstraZeneca in the area of psoriasis. The drug, brodalumab, was previously partnered with Amgen but the … Continue reading
Biotech M&A Continues to Climb the Curve
The trajectory of biotech M&A has been steep in 2015, so the $7.2bn acquisition of Receptos by oncology powerhouse Celgene, increases the gradient even further. This deal came out of left field, especially as commentators were still raking over the … Continue reading
Merck announces collaboration with Advaxis
Authored by James Sheppard The global pharmaceutical giant Merck & Co announced it had partnered with the New Jersey based biotech company Advaxis. The collaboration will see the pair test experimental immuno-oncology drug in combination with a high-profile immunotherapy drug … Continue reading
UK Government names biotech veteran Minister for Life Sciences
Authored by James Sheppard The UK government has announced it has created a new role of Minister for Life Sciences to which it has appointed former biotech venture capitalist George Freeman. Mr Freeman has a long history is biotech having … Continue reading
13 Life Science Leaders to watch in 2013 – The Verdict!
Authored by Liftstream In January 2013, Liftstream highlighted 13 people we thought the life sciences industry should be watching during 2013 as they took on unique challenges that we marked out for the year ahead. This January, we look back … Continue reading
ADC Therapeutics executives on fast track with funding and partners
Authored by James Sheppard ADC Therapeutics was launched in 2012 after Auven Therapeutics (previously known as Celtic Therapeutics) launched the company with initial funding of $50m. These funds were further added to buy Auven Therapeutics and Medimmune (part of AstraZeneca) … Continue reading
CFO appointments no longer just a numbers game
Authored by Karl Simpson AstraZeneca’s CEO, Pascal Soriot, recently said when announcing the newly appointed CFO Marc Dunoyer that he offered a blend of strategic thinking and financial expertise. Mr. Dunoyer joined AstraZeneca earlier this year from GSK where he … Continue reading
Roche Returns to Antibiotics with Polyphor Deal
Authored by James Sheppard Swiss pharmaceutical giant Roche signalled its return to the antibiotics market with its $560m deal for the rights to Swiss biotech Polyphor’s experimental antibiotic. The deal will see Polyphor receive $40m upfront and a further $520m … Continue reading